CDEK
← All drugs Report issue

dimethyltryptamine

Small moleculeexperimental

Dimethyltryptamine (DMT), also known as N,N-dimethyltryptamine (N,N-DMT), is a serotonergic hallucinogen and investigational drug of the tryptamine family that occurs naturally in many plants and animals. DMT is used as a psychedelic drug and prepared by various cultures for ritual purposes as an entheogen. — Wikipedia

Clinical trial activity

31 trials · 24 clinical orgs · 0 marketing orgs

Phase 1
26
Phase 2
5
Phase 3
1
Phase 4
0

Earliest trial started Apr 1, 2014 (NCT02033707)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 3 Sponsor(trial)

2020s

  1. Jan 1, 2023

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)CCc1c[nH]c2ccccc12
Mol. weight
188.27 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • dmt
  • dmt

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07244328Early Phase 1 (Phase 1)Nov 15, 2025Government of China, Zhejiang University
NCT06927076N/AAug 5, 2025University of Basel
NCT06899334Phase 1Apr 1, 2025University of Basel
NCT06772753Phase 1Feb 5, 2025Johns Hopkins University
NCT06524830Phase 2Dec 31, 2024atai Therapeutics, Inc., CenExel iResearch, LLC
NCT06671977Phase 1Nov 1, 2024Yale University
NCT06511947Phase 1Aug 1, 2024GH Research Limited
NCT06180759Phase 1May 1, 2024University of Basel
NCT05695495Phase 1Mar 15, 2024University of Basel
NCT06252506Phase 1Jan 22, 2024University of Bern, University of Zurich
NCT06070649Phase 1Jan 17, 2024National Institute on Alcohol Abuse and Alcoholism (NIAAA), Yale University
NCT06094907Phase 2Oct 9, 2023Universidade Federal do Rio Grande do Norte
NCT05829603Phase 1May 5, 2023Reconnect Labs, University of Zurich
NCT05901012Phase 1Apr 26, 2023Universidade Federal do Rio Grande do Norte
NCT05780216Early Phase 1 (Phase 1)Feb 20, 2023University of Freiburg, University of Zurich
NCT05644093Phase 1Jan 31, 2023Small Pharma Ltd
NCT05553691Phase 1Dec 31, 2022MAC Clinical Research, Small Pharma Ltd
NCT05753956Phase 1Dec 22, 2022GH Research Limited
NCT05559931Phase 1Nov 30, 2022Algernon Pharmaceuticals, Leiden University
NCT05384678Phase 1Nov 15, 2022University of Basel
Showing 20 of 31 trials
Page 1 / 2

Organizations

Research & Development (24)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of BaselAcademic/Hospital7622020
GH Research LimitedFor profit5522019
University of ZurichAcademic/Hospital4212020
Small Pharma LtdFor profit3322021
Universidade Federal do Rio Grande do NorteAcademic/Hospital3222022
Yale UniversityAcademic/Hospital3312021
Johns Hopkins UniversityAcademic/Hospital2212014
Algernon PharmaceuticalsFor profit1112022
atai Therapeutics, Inc.For profit1112024
Biomind Labs Inc.For profit1112022
CenExel iResearch, LLCFor profit1012024
Chong Kun Dang PharmaceuticalFor profit1112018
Free University of AmsterdamAcademic/Hospital1112020
Government of ChinaGovernment1012025
Hammersmith Medicines ResearchFor profit1012021
Imperial College LondonAcademic/Hospital1012021
Leiden UniversityAcademic/Hospital1012022
MAC Clinical ResearchFor profit1012022
National Institute on Alcohol Abuse and Alcoholism (NIAAA)Government1012024
Oxford Therapeutics Consulting LimitedFor profit1012021
24 organizations
Page 1 / 2